Startups
2020
1-10 Employees
PsyCurioPsyCurio is a NeuroTech Startup that combines data-driven feedback, experience simulation and neurpscience for training emotional regulation and cognitive functioning. We offer packages for companies for employee training and health management. And we are known in Europe for our ambient, fully immersive psychotherapy experience in VR that optimally meets the needs of humans' brains. It's a CE-certified B2B SaaS Medical Product in Europe that was developed in close collaboration with and is used by Europe's leading clinics. The team has a strong background in the field (serial founders, each between 7-12 years of experience in healthtech, sales, business dev, previous track record e.g. previous Exits) and was awarded multiple times by e.g. the German Federal Ministry of Economics & deutscher Startup Verband. PsyCurio already faces high demand by clinics in D-A-CH (Germany-Austria-Switzerland). With the german Accelerator Life science ( the market access program supported by the german covernment) PsyCurio now started the market entry in the US.
Address
Kinderhauser Straße 213, 48147 Münster, Germany
Details
Business Model
We have two models. Firstly, a Software-as-a-Service model, where customers pay a monthly fee to use our software. This model is usually used by larger clinics. Secondly, a pay-per-use model where customers pay per therapeutic session started. This model is usually used by private practitioners. USP
PsyCurio's USP is the integration of physiological parameters into the therapeutic process. Depending on detected physiological states of a patient - like arousal, or calmness - therapists can intervene, interact with patients, or adjust the VR immersion to increase effectiveness of the therapy according to the individual requirements and therapeutical progress of patients.
While there are competitors in the European and the American market which utilise virtual reality systems for the treatment of mental illnesses, none of them attempt to integrate physiological parameters of patients into their therapeutic approach, thus, missing out on increasing efficacy and reducing time and cost for therapies.